Seizures and extrapyramidal symptoms in a patient with Tourette's syndrome, Asperger's syndrome, and multiple sclerosis treated with interferon β-1a and clomipramine

Pharmacotherapy

Volumn 22, Issue 11, 2002, Pages 1504-1507

  Dubisar, Beth M ^a   Stoner, Steven C ^a,b   Khan, Rintu ^a   Farrar, Cynthia D ^a  

^a Northwest Missouri Psychiatric Rehabilitation Center   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; CLOMIPRAMINE; CLONIDINE; DESMOPRESSIN; FLUOXETINE; GLATIRAMER; GUANFACINE; METHYLPHENIDATE; OXCARBAZEPINE; PEMOLINE; PROPRANOLOL; RISPERIDONE; VALPROATE SEMISODIUM;

ADULT; ARTICLE; ASPERGER SYNDROME; CASE REPORT; CLINICAL FEATURE; COGNITIVE DEFECT; DEPRESSION; DRUG EFFECT; ENURESIS; EXTRAPYRAMIDAL SYMPTOM; GILLES DE LA TOURETTE SYNDROME; GRAND MAL SEIZURE; HUMAN; HYPERSALIVATION; MALE; MULTIPLE SCLEROSIS; PARKINSONISM; PEDOPHILIA;

EID: 0036842315     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.22.16.1504.33693     Document Type: Article

References (9)

1. Wynn DR, Rodriguez M, O'Fallon WM, Kurland LT. A reappraisal of the epidemiology of multiple sclerosis in Olmstead County, Minnesota. Neurology 1990;40:780-6.
2. Olafsson E, Benedikz J. Prevalence and prognosis of epilepsy in patients with multiple sclerosis. Epilepsia 1990;40:745-7.
3. Nyquist PA, Cascino GD, Rodriguez M. Seizures in patients with multiple sclerosis seen at Mayo Clinic, Rochester, Minnesota, 1990-1998. Mayo Clin Proc 2001;76(10):983-6.
4. Biogen, Inc. Avonex (interferon β-1a) Package Insert. Cambridge, MA; 1996.
5. American Psychiatric Association. Practice guidelines for the treatment of patients with bipolar disorder. Am J Psychiatry 1994;151(suppl):12.
6. Noseworthy J, Gold R, Hartung H. Treatment of multiple sclerosis: Recent trials and future perspectives. Curr Opin Neurol 1999;12(3):279-93.
7. Dion Y, Annable L, Sandor P, Chouinard G. Risperidone in the treatment of Tourette syndrome: A double-blind, placebo-controlled trial. J Clin Psychopharmacol 2002;22(1):31-9.
8. Polman, C. Drug treatment of multiple sclerosis. BMJ 2000;321(7259):490-4.
9. Silver H, Aharon N, Schwartz M. Attention deficit-hyperactivity disorder may be a risk factor for treatment-emergent tardive dyskinesia induced by risperidone. J Clin Psychopharmacol 2000;20(1):112-14.